FCN-159 is an orally effective selective MEK1/2 inhibitor and a prospective targeted therapy drug for tumors mutated by BRAF or RAS.

Zenocutuzumab is a bispecific antibody targeting HER2/HER3 developed by Merus NV. On July 7, 2023, the U.S. FDA granted Zenocutuzumab breakthrough therapy desig-nation for NRG1 fusion-positive non-small cell lung cancer.

Selinexor, a small molecule drug targeting XPO1, is developed by Karyopharm Therapeutics, Inc.

Lanifibranor, a small-molecule drug targeting PPARα + PPARγ + PPARδ, was initially developed by AbbVie, Inc.

Brogidirsen is a drug targeting DMD exon 44 antisense oligonucleotide, developed by Nippon Shinyaku Co.

Fruquintinib is a small molecule drug targeting VEGFR1, VEGFR2, and VEGFR3. This drug was initially developed by Hutchison Whampoa Medicine (Shanghai) Co., Ltd.

Anthrax Vaccine Adsorbed, Adjuvanted, com-mercially known as CYFENDUS, is a preventive vaccine targeting TLR9.

the approved dose for BMS's Deucravacitinib treatment of psoriasis is 6mg QD, whereas the estimated dose for TAK279 clinical treatment of psoriasis is over 30mg QD. Why does TAK279 have BIC potential?

Betibeglogene autotemcel, also known as Lovotibeglogene autotemcel and marketed as ZYNTEGLO, is an intravenous injection developed by bluebird bio, Inc.

Dostarlimab gxly, trade name JEMPERLI, is a monoclonal antibody targeting PD-1, originally discovered by AnaptysBio, Inc., and signed a cooperation and exclusive license agreement with TESARO, Inc. (a GSK subsidiary) in March 2014.

Iptacopan, also known as LNP023, is the first oral small moleculecompletion factor B (CFB) inhibitor developed by Novartis Pharma AG.

PRGN-2012 is a therapeutic vaccine that achieves therapeutic effects through immune stimulation.